疫苗接种与儿童免疫球蛋白A血管炎发病风险的关联

曹峰; 徐龙伟; 张迎辉

doi:10.7499/j.issn.1008-8830.2303129

PDF(529 KB)

HTML

中国当代儿科杂志 ›› 2023, Vol. 25 ›› Issue (11) : 1137-1142. DOI: 10.7499/j.issn.1008-8830.2303129

论著·临床研究

疫苗接种与儿童免疫球蛋白A血管炎发病风险的关联

曹峰, 徐龙伟, 张迎辉

作者信息 +

Association between vaccination and the risk of immunoglobulin A vasculitis in children

CAO Feng, XU Long-Wei, ZHANG Ying-Hui

Author information +

文章历史 +

摘要

目的探究疫苗接种对儿童免疫球蛋白A血管炎（immunoglobulin A vasculitis, IgAV）短期发病风险的影响。方法回顾性分析2021年11月—2023年1月郑州大学附属儿童医院住院治疗的IgAV患儿一般资料及发病前1年内疫苗接种史。通过自身对照-病例交叉分析方法，比较IgAV发病前3个月风险期和对照期的疫苗暴露率，计算比值比（odds ratio, OR）和95%置信区间（confidence interval, CI），同时进行1个月、2个月风险期的敏感性分析。结果纳入193例IgAV患儿，中位年龄为7.0岁；36例（18.7%）在发病前1年内至少接种1次疫苗，14例（7.3%）在3个月风险期至少接种1次疫苗。与未接种疫苗组相比，接种疫苗组IgAV发病年龄更小，差异有统计学意义（P<0.05）。两组胃肠道受累、肾脏受累、关节受累患儿比例的比较差异无统计学意义（P>0.05）。发病前3个月内接种任意种类疫苗与IgAV发病风险的OR值为2.08（95%CI：0.82~5.27，P>0.05）。进一步对1个月、2个月风险期进行敏感性分析，显示接种任意种类疫苗与IgAV发病风险的OR值分别为2.74（95%CI：0.72~10.48）、2.72（95%CI：0.95~7.77），均无统计学意义（P>0.05）。结论疫苗接种未增加儿童IgAV发病风险，也未使IgAV患儿临床症状加重。

Abstract

Objective To study the effect of vaccination on the short-term risk of immunoglobulin A vasculitis (IgAV) in children. Methods A retrospective analysis was conducted on the general data and the vaccination history within one year prior to onset in children with IgAV hospitalized in the Children's Hospital Affiliated to Zhengzhou University from November 2021 to January 2023. Vaccine exposure rates in the risk period (3 months prior to IgAV onset) and the control period were compared by autocontrol-case crossover analysis, and the odds ratio and 95% confidence interval (95%CI) were calculated. A sensitivity analysis for the one-month and two-month risk periods was conducted. Results A total of 193 children with IgAV were included, with a median age of 7.0 years. Among the 193 children, 36 (18.7%) received at least one dose of the vaccine within 1 year prior to IgAV onset, and 14 (7.3%) received at least one dose of the vaccine during the 3-month risk period. Compared to the unvaccinated IgAV group, the vaccinated IgAV group had a significantly younger age of onset (P<0.05). There were no significant differences in the proportions of children with gastrointestinal involvement, renal involvement, and joint involvement between the two groups (P>0.05). The odds ratio for developing IgAV after receiving any type of vaccine within 3 months prior to IgAV onset was 2.08 (95%CI: 0.82-5.27, P>0.05). Further sensitivity analysis for the 1-month and 2-month risk periods demonstrated that the odds ratios for developing IgAV after receiving any type of vaccine were 2.74 (95%CI: 0.72-10.48, P>0.05) and 2.72 (95%CI: 0.95-7.77, P>0.05), respectively. Conclusions Vaccination dose not increase the risk of IgAV, nor does it exacerbate clinical symptoms in children with IgAV.

导出引用

曹峰, 徐龙伟, 张迎辉. 疫苗接种与儿童免疫球蛋白A血管炎发病风险的关联[J]. 中国当代儿科杂志. 2023, 25(11): 1137-1142 https://doi.org/10.7499/j.issn.1008-8830.2303129

CAO Feng, XU Long-Wei, ZHANG Ying-Hui. Association between vaccination and the risk of immunoglobulin A vasculitis in children[J]. Chinese Journal of Contemporary Pediatrics. 2023, 25(11): 1137-1142 https://doi.org/10.7499/j.issn.1008-8830.2303129

参考文献

1 Ozen S, Marks SD, Brogan P, et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis: the SHARE initiative[J]. Rheumatology (Oxford), 2019, 58(9): 1607-1616. PMID: 30879080. DOI: 10.1093/rheumatology/kez041.
2 Pillebout E, Sunderk?tter C. IgA vasculitis[J]. Semin Immunopathol, 2021, 43(5): 729-738. PMID: 34170395. DOI: 10.1007/s00281-021-00874-9.
3 Nikolaishvili M, Pazhava A, Di Lernia V. Viral infections may be associated with Henoch-Sch?nlein purpura[J]. J Clin Med, 2023, 12(2): 697. PMID: 36675626. PMCID: PMC9862009. DOI: 10.3390/jcm12020697.
4 史淑芬, 孙穆, 王庆, 等. 强化免疫接种麻疹减毒活疫苗偶合过敏性紫癜一例[J]. 中国全科医学, 2011, 14(12): 1396. DOI: 10.3969/j.issn.1007-9572.2011.12.042.
5 Shu M, Liu Q, Wang J, et al. Measles vaccine adverse events reported in the mass vaccination campaign of Sichuan province, China from 2007 to 2008[J]. Vaccine, 2011, 29(18): 3507-3510. PMID: 19909830. DOI: 10.1016/j.vaccine.2009.10.106.
6 Ledford DK. Henoch-Sch?nlein purpura and influenza vaccine[J]. J Allergy Clin Immunol Pract, 2017, 5(1): 210. PMID: 28065339. DOI: 10.1016/j.jaip.2016.05.022.
7 Watanabe T. Henoch-Sch?nlein purpura following influenza vaccinations during the pandemic of influenza A (H1N1)[J]. Pediatr Nephrol, 2011, 26(5): 795-798. PMID: 21120537. DOI: 10.1007/s00467-010-1722-8.
8 Esposito S, Mariotti Zani E, Torelli L, et al. Childhood vaccinations and type 1 diabetes[J]. Front Immunol, 2021, 12: 667889. PMID: 34512622. PMCID: PMC8427438. DOI: 10.3389/fimmu.2021.667889.
9 Jain E, Donowitz JR, Aarons E, et al. Multisystem inflammatory syndrome in children after SARS-CoV-2 vaccination[J]. Emerg Infect Dis, 2022, 28(5): 990-993. PMID: 35275051. PMCID: PMC9045439. DOI: 10.3201/eid2805.212418.
10 傅桐, 杜悦. 儿童IgA血管炎诊断与治疗[J]. 中国实用儿科杂志, 2022, 37(1): 17-21. DOI: 10.19538/j.ek2022010604.
11 Murata K, Onoyama S, Yamamura K, et al. Kawasaki disease and vaccination: prospective case-control and case-crossover studies among infants in Japan[J]. Vaccines (Basel), 2021, 9(8): 839. PMID: 34451964. PMCID: PMC8402330. DOI: 10.3390/vaccines9080839.
12 Piram M, Gonzalez Chiappe S, Madhi F, et al. Vaccination and risk of childhood IgA vasculitis[J]. Pediatrics, 2018, 142(5): e20180841. PMID: 30377240. DOI: 10.1542/peds.2018-0841.
13 Da Dalt L, Zerbinati C, Strafella MS, et al. Henoch-Sch?nlein purpura and drug and vaccine use in childhood: a case-control study[J]. Ital J Pediatr, 2016, 42(1): 60. PMID: 27316345. PMCID: PMC4912703. DOI: 10.1186/s13052-016-0267-2.
14 Xu Y, Wang JJ, Liu FF, et al. Predisposing factors of childhood Henoch-Sch?nlein purpura in Anhui province, China[J]. J Investig Med, 2019, 67(4): 771-778. PMID: 30530785. DOI: 10.1136/jim-2018-000906.
15 Jariwala S, Vernon N, Shliozberg J. Henoch-Sch?nlein purpura after hepatitis A vaccination[J]. Ann Allergy Asthma Immunol, 2011, 107(2): 180-181. PMID: 21802028. DOI: 10.1016/j.anai.2011.05.006.
16 Sexton K, McNicholas A, Galloway Y, et al. Henoch-Sch?nlein purpura and meningococcal B vaccination[J]. Arch Dis Child, 2009, 94(3): 224-226. PMID: 18650242. DOI: 10.1136/adc.2007.125195.
17 Anderson EJ, Daugherty MA, Pickering LK, et al. Protecting the community through child vaccination[J]. Clin Infect Dis, 2018, 67(3): 464-471. PMID: 29471452. DOI: 10.1093/cid/ciy142.
18 Hernandez Quiroz E, Kauffman CL, Kupiec-Banasikowska A. Erythema multiforme following hepatitis a and pneumococcal vaccinations[J]. Yale J Biol Med, 2022, 95(2): 213-215. PMID: 35782476. PMCID: PMC9235263.
19 Nakayama T. Causal relationship between immunological responses and adverse reactions following vaccination[J]. Vaccine, 2019, 37(2): 366-371. PMID: 30503656. DOI: 10.1016/j.vaccine.2018.11.045.
20 McNeil MM, DeStefano F. Vaccine-associated hypersensitivity[J]. J Allergy Clin Immunol, 2018, 141(2): 463-472. PMID: 29413255. PMCID: PMC6602527. DOI: 10.1016/j.jaci.2017.12.971.
21 Roth GA, Picece VCTM, Ou BS, et al. Designing spatial and temporal control of vaccine responses[J]. Nat Rev Mater, 2022, 7(3): 174-195. PMID: 34603749. PMCID: PMC8477997. DOI: 10.1038/s41578-021-00372-2.
22 马超, 安志杰, 曾玫, 等. 《国家免疫规划疫苗儿童免疫程序及说明（2021年版）》要点解析[J]. 中国疫苗和免疫, 2021, 27(3): 235-241. DOI: 10.19914/j.CJVI.2021041.
23 Woolley P, Tailor A, Shah R, et al. Real-world, single-center experience of SARS-CoV-2 vaccination in immune thrombocytopenia[J]. J Thromb Haemost, 2022, 20(6): 1476-1484. PMID: 35313390. PMCID: PMC9115165. DOI: 10.1111/jth.15704.
24 Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group[J]. N Engl J Med, 2001, 344(5): 319-326. PMID: 11172162. DOI: 10.1056/NEJM200102013440501.
25 Chen Y, Zhang J, Chu X, et al. Vaccines and the risk of Guillain-Barré syndrome[J]. Eur J Epidemiol, 2020, 35(4): 363-370. PMID: 31858323. DOI: 10.1007/s10654-019-00596-1.
26 Zuber PLF, Gruber M, Kaslow DC, et al. Evolving pharmacovigilance requirements with novel vaccines and vaccine components[J]. BMJ Glob Health, 2021, 6(Suppl 2): e003403. PMID: 34011500. PMCID: PMC8137242. DOI: 10.1136/bmjgh-2020-003403.
27 Ali A, Waris A, Khan MA, et al. Recent advancement, immune responses, and mechanism of action of various vaccines against intracellular bacterial infections[J]. Life Sci, 2023, 314: 121332. PMID: 36584914. DOI: 10.1016/j.lfs.2022.121332.
28 Di Pietrantonj C, Rivetti A, Marchione P, et al. Vaccines for measles, mumps, rubella, and varicella in children[J]. Cochrane Database Syst Rev, 2021, 11(11): CD004407. PMID: 34806766. PMCID: PMC8607336. DOI: 10.1002/14651858.CD004407.pub5.
29 Gan G, Liu H, Liang Z, et al. Vaccine-associated thrombocytopenia[J]. Thromb Res, 2022, 220: 12-20. PMID: 36265409. DOI: 10.1016/j.thromres.2022.09.017.